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Abstract
Studies of differential gene expression have identified several molecular signatures and
pathways associated with Parkinson’s disease (PD). The role of isoform switches and
differential transcript usage (DTU) remains, however, unexplored. Here, we report the first
genome-wide study of DTU in PD. We performed RNA sequencing following ribosomal
RNA depletion in prefrontal cortex samples of 49 individuals from two independent case-
control cohorts. DTU was assessed using two transcript-count based approaches, imple-
mented in the DRIMSeq and DEXSeq tools. Multiple PD-associated DTU events were
detected in each cohort, of which 23 DTU events in 19 genes replicated across both patient
cohorts. For several of these, including THEM5, SLC16A1 and BCHE, DTU was predicted
to have substantial functional consequences, such as altered subcellular localization or
switching to non-protein coding isoforms. Furthermore, genes with PD-associated DTU
were enriched in functional pathways previously linked to PD, including reactive oxygen spe-
cies generation and protein homeostasis. Importantly, the vast majority of genes exhibiting
DTU were not differentially expressed at the gene-level and were therefore not identified by
conventional differential gene expression analysis. Our findings provide the first insight into
the DTU landscape of PD and identify novel disease-associated genes. Moreover, we show
that DTU may have important functional consequences in the PD brain, since it is predicted
to alter the functional composition of the proteome. Based on these results, we propose
that DTU analysis is an essential complement to differential gene expression studies in
order to provide a more accurate and complete picture of disease-associated transcriptomic
alterations.
Author summary
Altered expression has been found at the level of genes and pathways in the brain of indi-
viduals with Parkinson’s disease but remains unexplored at the level of individual tran-
scripts. Thus, it is largely unknown whether transcript-specific events, for instance due to
altered splicing or post-transcriptional modifications, occur in the Parkinson’s disease
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brain. Using RNA sequencing data from 49 brain samples, we performed a transcrip-
tome-wide study of differential transcript usage in Parkinson’s disease. We identified tran-
script-specific changes in multiple genes, and many of these were predicted to have
important functional consequences on the encoded protein, such as altered subcellular
localization or total protein levels. Interestingly, the vast majority of these transcript-spe-
cific changes were not detected by conventional differential gene expression analysis.
Our findings suggest that analyses of differential transcript usage can provide additional
insight into the transcriptomic landscape of complex brain disorders.
Introduction
Parkinson’s disease (PD) is the second most prevalent neurodegenerative disorder, affecting
more than 1% of the population above the age of 60 years [1]. Both genetic and environmental
factors influence the risk of PD, but the molecular mechanisms underlying disease initiation
and progression remain unknown. Studies of differential gene expression (DGE) employing
microarrays or RNA sequencing (RNA-Seq) have identified molecular signatures associated
with PD, including various aspects of mitochondrial function, protein degradation, neuroin-
flammation, vesicular transport and synaptic transmission [2].
An important limitation of DGE studies, however, is that they do not account for isoform
diversity. Most genes encode more than one transcript isoform (henceforth called isoform),
arising from alternative splicing, alternative usage of transcription start sites, or post-transcrip-
tional regulation events such as alternative cleavage and polyadenylation [3]. Distinguishing
between isoforms is essential, as these can encode proteins with different functions and/or sub-
cellular localizations, or no protein product at all. Isoforms can also be associated with varying
degrees of mRNA stability, for example by varying the length of the 3’-untranslated regions,
which ultimately influences the rate of translation and hence the quantity of the encoded pro-
tein [4]. Moreover, differential splicing can impact cellular function without causing major
changes on the levels of expressed protein. The diversity of tissue-specific isoform expression
patterns is mainly attributed to differential usage of untranslated transcripts and/or non-prin-
cipal isoforms, suggesting that even small changes in isoform usage can have a substantial
effect on the composition and function of the proteome [5].
An efficient method to characterize differences in the isoform landscape is via differential
transcript usage (DTU) analysis. DTU is a measure of the relative contribution of one tran-
script to the overall expression of the gene (i.e. the total transcriptional output). The analysis is
based on individual transcript read counts normalized to the sum of all transcript read counts
of the gene. This sets DTU apart from differential transcript expression (DTE), where the indi-
vidual transcript counts are investigated independently from the context of the total transcrip-
tional output. DTU requires at least one DTE event for the usage ratio between the transcripts
of a gene to change. In contrast, DTE can occur without DTU, when the expression of an
isoform is altered but its relative contribution to the total transcriptional output remains
unchanged [6].
Individual transcript-level information—DTE or DTU—is lost in conventional DGE analy-
sis, where the counts of individual transcripts are collapsed at the gene level. DTU events
changing in opposite directions (e.g. when one transcript is up-regulated and another down-
regulated) may cancel out at the gene level. Thus, transcript usage quantification has the poten-
tial to identify candidate genes and processes which would otherwise remain concealed in tra-
ditional DGE and DTE studies.
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In the human brain, specific transcript usage profiles have been associated with neuronal
development and aging [7] as well as with disease [8], including neurodegeneration [9, 10].
Current evidence suggests that differential splicing and DTU may be implicated in PD [11].
Disease-associated alternative splicing has been reported for genes linked to idiopathic and
monogenic PD, including SNCA [12], PRKN [12, 13] and PARK7 [14]. With the exception of
these targeted, hypothesis-based studies, however, the role of DTU in PD remains largely
unexplored and no genome-wide DTU studies have been carried out to date.
In the present study we report the first genome-wide analysis of DTU in PD. We show that
DTU does occur in the PD brain and identify genes that show robust, altered isoform ratios
across two separate cohorts of individuals with idiopathic PD and neurologically healthy con-
trols: a discovery cohort from the Park West study [15] (n = 28) and a replication cohort from
the Netherlands Brain Bank (n = 21).
Results
Multiple DTU events are detected in the PD prefrontal cortex
We first analyzed RNA-Seq data from the prefrontal cortex of our discovery cohort (n = 17/11
PD/controls; Table A in S1 File), using two alternative approaches (DRIMSeq [16] and DEX-
Seq [17]) to characterize DTU between PD and controls. Statistically significant DTU surviv-
ing multiple testing correction are referred to as DTU events and a gene exhibiting at least one
DTU event is referred to as a DTU gene (detailed definitions are provided in the Methods).
In the discovery cohort, DTU analysis was based on n = 40, 520 transcripts and identified
814 DTU events in 584 DTU genes. The analysis with DEXSeq identified 254 DTU genes and
495 DTU genes were reported by DRIMSeq, with 165 detected by both methods (Fig 1A). The
number of single DTU events per DTU gene ranged from one to three (Table 1). The most
common Ensembl transcript biotype involved in DTU events was “protein coding” for both
DEXSeq and DRIMSeq, followed by “processed transcript” (i.e., transcripts not containing an
ORF) and “retained intron” (i.e., transcripts containing intronic sequences) (Fig 1B). We
tested for overrepresentation of DTU events across transcript biotypes using Fisher’s exact test
and found that DTU events were overrepresented in 3 categories for DRIMSeq after multiple
testing correction at alpha 0.05 (protein coding, retained intron, antisense). Although no cate-
gories were significantly overrepresented after Bonferroni correction using DEXSeq, the low-
est p-values were for “antisense” and “protein coding”, in agreement with DRIMSeq. Test
statistics for each of the biotype categories are listed in S1 Table.
Visualization of the overall behavior of the effect size as a function of the mean transcript
expression (MA-plot) and nominal transcript significance (Volcano-plot) are shown in S1A
and S1B Fig. The p-value distribution varied depending on the number of transcripts a gene
possessed. This variation behaved differently in DRIMSeq and DEXSeq—the p-value distribu-
tion became more uneven with increasing numbers of transcripts in DRIMSeq and decreasing
number of transcripts in DEXSeq (S2C Fig). A list of identified DTU events is provided in
Table B in S1 File.
Gene-set enrichment analysis (GSEA) of the DTU genes showed clusters of enriched path-
ways related to regulation of cell development, identical protein binding and perinuclear
region of cytoplasm as the top most significant in each of the GO Ontology categories (Biologi-
cal process, Molecular function, Cellular component) (Table 2).
To validate our methodology, we sought to confirm relative transcript abundances of genes
with a DTU event by quantitative PCR (qPCR). To this end, we selected two genes fulfilling
the following criteria: i) adequate individual transcript expression levels (i.e., the transcript
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Fig 1. Overlap of DTU genes and transcripts between DEXSeq and DRIMSeq. A: Venn diagram showing the overlap between DTU genes
resulting from analyses using DEXSeq and DRIMSeq, and genes that show DGE in the discovery cohort. B: Distribution of DTU events across
defined transcript biotypes for each of the two tools (panels). Transcript biotypes are arranged on the y-axis, with the percentage of DTU events in
each biotype category of all tool-specific DTU events represented on the x-axis. Text labels show the percentage of DTU events relative to the
number of transcripts tested in each biotype category.
https://doi.org/10.1371/journal.pgen.1009182.g001
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was present in both cohorts after pre-filtering and detectable by qPCR) and ii) sufficiently dis-
tinct exonic composition of the individual transcripts to allow transcript-specific amplification
(i.e., it was possible to design individual primer pairs that would detect one specific transcript
variant alone). The genes ZNF189 and BCHE satisfied all criteria and their transcript variants
could be successfully amplified, serving as a proof-of-principle target (Fig 2A). The qPCR
Table 1. Distribution of the number of DTU events per gene.
Tool 1 transcript 2 transcripts 3 transcripts
DEXSeq 173 76 5
DRIMSeq 312 181 2
https://doi.org/10.1371/journal.pgen.1009182.t001
Table 2. Enriched GO pathway clusters.
Pathway p-value
GO biological process
regulation of cell development 6.62 � 10−14
regulation of nitric oxide biosynthetic process 1.96 � 10−10
mitotic cell cycle 6.43 � 10−10
regulation of transport 1.71 � 10−08
nuclear DNA replication 1.20 � 10−06
regulation of cellular component size 1.46 � 10−06
phosphate-containing compound metabolic process 5.51 � 10−06
single-organism catabolic process 5.65 � 10−06
negative regulation of transcription, DNA-templated 2.45 � 10−05
neurotrophin TRK receptor signaling pathway 3.52 � 10−05
GO molecular functions
identical protein binding 7.26 � 10−16
nucleic acid binding transcription factor activity 2.15 � 10−10
ubiquitin-protein transferase activity 1.78 � 10−08
protein kinase binding 7.60 � 10−08
zinc ion binding 6.15 � 10−06
substrate-specific transporter activity 7.63 � 10−05
transcription cofactor activity 8.21 � 10−05
protein serine/threonine kinase activity 1.26 � 10−03
DNA-directed DNA polymerase activity3 1.82 � 10−03
Ras guanyl-nucleotide exchange factor activity 2.41 � 10−03
GO cellular component
perinuclear region of cytoplasm 2.32 � 10−04
nuclear speck 9.90 � 10−04
nuclear chromosome part 4.04 � 10−03
plasma membrane part 1.33 � 10−02
intercellular bridge 1.56 � 10−02
cell projection 1.74 � 10−02
nuclear envelope 1.95 � 10−02
nucleolus 3.10 � 10−02
membrane protein complex 3.18 � 10−02
Displayed are the titles of each pathway cluster. A cluster consists of multiple pathways that share a set of genes and
have shown high overlap. Only significant pathways after correction have been considered for the clustering. The list
of clusters is sorted by the aggregated p-values of each pathway in one cluster.
https://doi.org/10.1371/journal.pgen.1009182.t002
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analysis replicated the results of the RNA-Seq-based DTU analyses for two of the three iso-
forms of ZNF189 (ENST00000374861 and ENST00000259395), while the third isoform
(ENST00000339664) appeared unchanged (Fig 2B). The qPCR analysis for BCHE confirmed
the increased relative expression of isoform ENST00000540653 and the decreased relative
expression of isform ENST00000264381 (Fig 2B).
Pre-filtering reduces transcriptome complexity
To reduce the false discovery rate (FDR), transcripts and genes underwent a pre-filtering
based on a minimum expression level prior to the analysis (see Methods). This pre-filtering
Fig 2. qPCR validation of ZNF189 and BCHE relative transcript abundances in individuals with PD and controls. A: Schematic representation of ZNF189 and
BCHE transcript variants analysed by qPCR. qPCR primer positions are indicated by arrows. B: Comparison of relative transcript abundances for the genes
ZNF189 and BCHE, obtained from RNASeq and qPCR. The upper row represents raw relative transcript abundances. Listed are only transcripts that remained after
filtering. Data points are grouped by condition on the x-axis (PD vs CT). The three data points per group represent the three samples selected for qPCR. The lower
row represents the results of qPCR analysis. Red lines show the mean of the respective group.
https://doi.org/10.1371/journal.pgen.1009182.g002
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affected the distribution of mean transcript expression and the mean number of transcripts
per gene. In the discovery cohort, 77% (n = 137, 437) of all transcripts and 75% (n = 38, 100) of
all genes were removed due to insufficient expression. Likewise, 82% (n = 143, 823) of all tran-
scripts and 78% (n = 39, 342) of all genes were filtered out in the replication cohort. The distri-
bution of mean transcript expression in the discovery cohort was shifted from a median of 15
read counts to 61, and from 12 to 63 in the replication cohort, after excluding low expressed
transcripts and genes. The filtering procedure reduced the standard deviation of the mean
transcript distribution in both cohorts from 30,753 to 432 in the discovery cohort, and from
39,096 to 484 in the replication cohort (Fig 3A). We also observed a reduction in the median
number of transcripts per gene, from 9 to 3 in the discovery cohort and from 10 to 3 in the rep-
lication cohort (Fig 3B). We also observed an increase in the relative amount of protein coding
transcripts as well as a decrease in the amount of pseudogene transcripts, snoRNAs, snRNAs,
miRNAs and rRNAs (Fig 3C).
Alternative DTU methods agree in effect size and are minimally influenced
by accounting for cell type composition
We investigated the agreement of effect size (i.e., the modeled coefficient for the disease state)
in terms of magnitude and direction between the two tools in the discovery cohort. Overall,
both methods agreed on the estimated effect size (R = 0.97, p = 2.2 � 10−16, n = 40, 520) and the
concordance was even more pronounced in the subset of DTU events that were significant for
either one of the cohorts (R = 0.98, p = 2.2 � 10−16, n = 813) (Fig 4). The general trend of statisti-
cal significance showed that transcripts which were identified as DTU events by at least one
of the methods were likely to be defined at least as nominally significant by the alternative
method: 97% of all DRIMSeq DTU events were nominally significant according to DEXSeq
and 98% of all DEXSeq DTU events were reported as nominally significant by DRIMSeq. The
concordance between the two methods in the replication cohort is shown in S2 Fig. We have
recently shown that cell type heterogeneity can have a substantial impact on DGE analyses in
bulk brain tissue [18]. To determine whether this also applied to our DTU analyses, we
assessed the effect of accounting for cell type composition on our results. To this end, we
obtained relative cellularity estimates (marker gene profiles, MGPs) for the cortical cell-types
that were shown to be significantly associated with disease status (oligodendrocytes and micro-
glia) in our previous study employing the same samples [18]. Accounting for cellular composi-
tion slightly increased the discovery signal, identifying a few more DTU genes with both
DRIMSeq and DEXSeq. This effect was minor, however, as most DTU genes and events were
identified irrespective of whether cell-type composition was accounted for or not (S3 and S4
Figs).
Most DTU events are not detected by conventional DGE analysis
Next, we sought to determine whether DTU events were detectable at the gene level by com-
paring the results of the DTU analysis to a conventional DGE analysis performed on the same
dataset [18]. We found that less than 3% (n = 13) of the DTU genes (n = 584) were also signifi-
cant at the gene level (BH corrected, FDR< 0.05) (Fig 1A), suggesting that compensatory
changes across transcripts can balance out overall gene expression. Indeed, in genes with two
DTU events, the effect size of these generally tended to move in opposite directions, canceling
out the change in overall gene expression (Fig 5A). Similarly, in genes with only one DTU
event, the effect size of DGE was smaller than the effect size of DTU, or even close to zero (Fig
5B), which likely originated from compensation distributed across multiple transcripts.
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Fig 3. Transcript filter statistics. Comparison of data distributions before and after filtering of low expressed transcripts and genes. A:
Log10 of the mean CPMs (counts per million) over all samples before and after filtering out low-expressed transcripts and genes. B: Violin
plots showing the distribution of the number of transcripts per gene (in logarithmic scale). Violin width is scaled by the total number of
observations while jittered points represent actual observations. C: Bar plot of transcript biotypes as defined by Ensemble v75 before and
after filtering. Displayed are the relative frequencies of each category normalized by the number of transcripts before and after filtering.
Categories with frequencies smaller than 0.001 were excluded for better visualization.
https://doi.org/10.1371/journal.pgen.1009182.g003
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Fig 4. Concordance between DEXSeq and DRIMSeq. Estimated transcript usage effect sizes are shown for each transcript
of the discovery cohort, with results from each tool on each of the axes (DRIMSeq x-axis, DEXSeq y-axis). Points situated
on the diagonal represent transcripts with equal effect size in both tools. Points situated inside the first and third quadrant
represent transcripts agreeing in direction across tools (i.e. first quadrant: up-regulated in PD, third quadrant: down-
regulated in PD). A: Transcripts that did not reach statistical significance in the DTU analyses by either DRIMSeq or
DEXSeq. B: Transcripts found to be significant by both tools. C: Transcripts found to be significant by DEXSeq only. D:
Transcripts found to be significant by DRIMSeq only. Transcripts identified as DTU events (significant after p-value
adjustment) are coloured according to the plot legend. Red: DTU event by both tools, blue: DTU event by DEXSeq only,
yellow: DTU event by DRIMSeq only, grey: transcript either did not survive FWER correction in any of the tools or was not
nominally significant.
https://doi.org/10.1371/journal.pgen.1009182.g004
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Fig 5. Concordance with DGE. The plot shows the relationship between the DTU effect size for each transcript (y-axis) and DGE effect size (x-
axis). Data points correspond to transcripts. The x-coordinate of each point represents the effect size estimated for its parent gene in DGE
analysis. The color scale indicates DGE significance after correction. A: DTU genes with 2 DTU events, with connected points representing each
of the events from the gene. B: DTU genes with a single DTU event.
https://doi.org/10.1371/journal.pgen.1009182.g005
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Only 13 DTU genes with at least one DTU event were also identified by DGE (Table 3). Six
of these genes had a single DTU event and the remaining 7 had multiple DTU events. Of the 6
genes with a single DTU event, 3 showed the same direction of change in both DGE and DTU,
whereas in the other 3, DGE and DTU indicated changes in opposite directions. For all 7 DTU
genes with multiple DTU events, at least one DTU event was in the opposite direction of the
DGE change. For example, while the protein coding transcript of the VWF gene was up-regu-
lated, DGE analysis showed down-regulation at the gene-level, driven by a non-protein coding
isoform. These results indicate that DTU analyses provide important additional insight into
the transcriptomic landscape of PD.
Detected DTU events replicated in an independent patient cohort
We replicated our findings using RNA-Seq data from an independent cohort from the Nether-
lands Brain Bank (n = 10/11 PD/controls; Table A in S1 File). A total of 32,040 transcripts
passed quality filtering in the replication cohort. The majority of these (n = 29, 807; 93%) over-
lapped with the pre-filtered transcripts of the discovery cohort and were further analyzed for
replication. A total of 10,713 transcripts from the discovery cohort, however, did not pass pre-
filtering in the replication cohort. Of these, 249 were identified as DTU events in the discovery
cohort (S5A Fig). To assess the overall concordance between the two cohorts, we divided the
common set of transcripts into 4 categories according to their nominal significance in differ-
ential usage in PD: i. non-significant in either cohort, ii. significant only in the discovery
cohort, iii. significant in both cohorts, iv. significant only in the replication cohort. For each
Table 3. DTU genes detected by DGE.
Tool Gene Transcript ID Biotype ES DTU ES DGE
DRIMSeq BCHE ENST00000540653 protein coding 1.81 -0.96
DRIMSeq BCHE ENST00000264381 protein coding -1.81 -0.96
DEXSeq DAAM2 ENST00000491083 processed transcript 0.99 -0.80
DRIMSeq EAF1-AS1 ENST00000610011 antisense 2.79 0.99
DRIMSeq FRG1B ENST00000439954 protein coding -0.77 -1.26
DRIMSeq FRG1B ENST00000358464 protein coding -0.79 -1.26
DRIMSeq FRG1B ENST00000479318 nonsense mediated decay 1.13 -1.26
DRIMSeq FRMPD2 ENST00000491130 retained intron -2.97 -1.17
DRIMSeq FRMPD2 ENST00000486151 retained intron 2.97 -1.17
DRIMSeq HIBCH ENST00000414928 nonsense mediated decay 1.58 0.88
DRIMSeq MIA ENST00000597600 protein coding -2.08 1.43
DRIMSeq MIA ENST00000593317 retained intron 2.08 1.43
DRIMSeq MMP24-AS1 ENST00000566203 antisense 0.91 -0.58
DRIMSeq PRODH ENST00000334029 protein coding -1.48 -1.17
DRIMSeq SLCO1A2 ENST00000452078 protein coding -0.83 -1.04
DRIMSeq SLCO1A2 ENST00000463718 retained intron 0.83 -1.04
DRIMSeq TSPAN15 ENST00000475069 retained intron 2.32 -0.84
DRIMSeq TSPAN15 ENST00000373290 protein coding -2.32 -0.84
DRIMSeq UFSP2 ENST00000509180 protein coding 1.22 -0.60
DRIMSeq VWF ENST00000538635 processed transcript -1.38 -0.93
DRIMSeq VWF ENST00000261405 protein coding 1.38 -0.93
Each transcript is described by its Ensemble identifier (version 75). The effect size (ES) is relative to the controls, i.e. positive ES represents an increase in PD relative to
controls, negative ES a decrease. All entries in the table represent DTU events of which the parent gene was detected by DGE (BH adjusted, FDR = 0.05). DTU events
that were identified by both DRIMSeq and DEXSeq are listed only with the estimated ES of DRIMSeq. The list is sorted by gene name in alphabetical order.
https://doi.org/10.1371/journal.pgen.1009182.t003
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category we assessed the concordance in DTU direction between the discovery and replication
cohort (Fig 6A). In the group of non-significant transcripts, we observed a low correlation in
the direction of DTU (Pearson’s R = 0.07, p = 2.2 � 10−16, n = 2, 5002), with only 54% of tran-
scripts agreeing between the cohorts. A higher correlation (Pearson’s R = 0.19, p = 2.2 � 10−16,
n = 3776) was observed for the group of transcripts which were nominally significant in the
discovery cohort only, where 59% of transcripts showed the same direction of change in both
cohorts. Transcripts which were significant only in the replication cohort showed no correla-
tion (Pearson’s R = 0.058, p = 0.092, n = 843) in the direction of DTU. The highest correlation
(Pearson’s R = 0.25, p = 0.6 � 10−3, n = 186) was observed in the group of transcripts that were
nominally significant in both cohorts, with a 62% concordance in direction.
When we reduced the collection of transcripts to DTU events detected in the discovery
cohort, we saw a high correlation (Pearson’s R = 0.28, n = 481, p = 2.5 � 10−10), with 64% of
these transcripts agreeing on the direction of change. This suggests that highly significant
DTU events identified in our discovery cohort show a similar trend in our replication cohort
(Fig 6B). Notably, 23% of the DTU genes identified in the discovery cohort were filtered out
during pre-processing of the replication cohort and thus were excluded from this analysis.
A total of 23 DTU events in 19 genes detected in the discovery cohort were concordant in
direction of change and nominally significant in the replication cohort (Table 4).
Among the 19 replicated DTU genes, 15 showed one DTU event and four comprised two
DTU events per gene. Interestingly, in the four genes exhibiting two DTU events (LINC00499,
BCHE, THEM5, SLC16A1), these moved in opposite directions. In BCHE and THEM5, DTU
resulted in isoform switches (i.e. two DTU events in opposite directions) between different
protein-coding transcripts. THEM5, encoding an acyl-CoA thioesterase involved in mitochon-
drial fatty acid metabolism, showed decreased usage of the full-length transcript (encoding a
247 amino acid protein) and increased usage of a shorter transcript (encoding a 119 amino
acid protein) in PD. The down-regulated, full-length isoform was predicted to localize to the
mitochondria (likelihood = 0.99), whereas the up-regulated, shorter isoform was more likely
to localize to the extracellular space (likelihood = 0.36) than to the mitochondria (likeli-
hood = 0.21). Hence, the decreased usage of the full-length isoform could result in a decrease
of mitochondrial THEM5 activity in PD. A similar pattern was observed for the BCHE gene,
encoding a butyrylcholinesterase, with the full-length isoform (encoding a protein of 602
amino acids) down-regulated in PD, and an up-regulated shorter transcript encoding a puta-
tive protein of 64 amino acids. While both isoforms were predicted to be soluble and localize
to the extracellular space, the shorter isoform lacks the substrate binding site located at posi-
tions 144 and 145 and it is therefore predicted to be non-functional, suggesting that BCHE
function may be down-regulated in PD. The SLC16A1 gene, encoding a lactate transporter in
oligodendroglia, showed a switch from a protein-coding to a non-protein coding isoform in
PD, revealing decreased expression of the protein coding transcript in PD.
In agreement with the down-regulation observed at the gene level, only 2 out of 19 repli-
cated genes with DTU showed a significant altered overall gene expression: BCHE and
PRODH (BH corrected, FDR< 0.05). In the case of BCHE, the down-regulation was observed
for the full-length transcript as described above. PRODH exhibited a single DTU event consist-
ing of a decreased relative expression of a protein-coding transcript variant in PD.
No evidence of DTU for genes linked to monogenic PD
Previous research had suggested that genes linked to monogenic PD, including SNCA, PARK7
and PRKN, may exhibit altered transcript expression patterns in idiopathic PD [11, 12, 14].
Therefore, we sought to investigate whether these observations replicate in our data.
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Fig 6. DTU replication in an independent cohort. Each data point corresponds to one transcript. The estimated effect size in the discovery cohort is represented on
the y-axis and the estimated effect size for the replication cohort on the x-axis. A: The overlapping set of transcripts between the two cohorts is divided into 4
categories depending on their nominal significance in either cohort according to DRIMSeq. Transcripts not found to be significant in any cohort are shown in the
lower left quadrant. Transcripts found to be significant in both cohorts in the upper right quadrant. Transcripts found to be significant only in the replication or in the
discovery cohort are in the upper left and lower right quadrant respectively. The color scale (red-gray) shows adjusted p-value in the discovery cohort. B: Displayed
are all DTU events (significant after correction) of the discovery cohort. Red color indicates nominal significance (before correction) in the replication cohort. The
two columns present the results obtained from each respective tool.
https://doi.org/10.1371/journal.pgen.1009182.g006
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Increased expression of four SNCA transcript variants, encoding the protein isoforms
SNCA-140, SNCA-126, SNCA-112 and SNCA-98, were reported in the prefrontal cortex of
individuals with PD [12]. None of these transcripts showed evidence of DTU in our analysis.
The transcript (ENST00000506244) encoding the full-length protein (SNCA-140), showed a
trend for reduced relative expression in PD, but this did not reach statistical significance
(p = 0.055, effect size = −0.48, DRIMSeq). In the same study, two out of seven protein-coding
splice variants of PRKN (TV3 and TV12) were suggested to be overexpressed in the PD brain.
In our data, only two PRKN transcript variants (TV1 and TV2) showed sufficient expression
to be analyzed, and neither of them showed statistical evidence of DTU (nominal p> 0.79,
absolute effect size < 0.09, DRIMSeq) in agreement with the results reported in [12].
Finally, one study reported that the altered relative transcript abundance of PARK7 in
blood may be used as a biomarker for PD [14]. None of the transcript variants of PARK7 were
sufficiently expressed in our dataset to investigate the transcript usage pattern of this gene in
the PD brain.
Table 4. Replicated DTU genes.
Tool Gene Transcript ID Biotype ES discovery cohort ES replication cohort
DEXSeq BCHE ENST00000264381 protein coding -1.78 -1.16
DEXSeq BCHE ENST00000540653 protein coding 1.79 1.16
DEXSeq XPA ENST00000375128 protein coding -1.18 -0.82
DEXSeq VWA9 ENST00000573314 nonsense mediated decay -1.81 -0.86
DRIMSeq SLC16A1 ENST00000369626 protein coding -1.02 -0.91
DRIMSeq SLC16A1 ENST00000478835 processed transcript 1.02 0.91
DRIMSeq THEM5 ENST00000453881 protein coding 1.74 1.77
DRIMSeq THEM5 ENST00000368817 protein coding -1.74 -1.77
DRIMSeq BCHE ENST00000540653 protein coding 1.81 1.06
DRIMSeq BCHE ENST00000264381 protein coding -1.81 -1.06
DRIMSeq HDAC3 ENST00000305264 protein coding -1.38 -0.63
DRIMSeq XPA ENST00000375128 protein coding -1.15 -0.78
DRIMSeq ZNF208 ENST00000601993 protein coding 1.13 1.07
DRIMSeq VWA9 ENST00000573314 nonsense mediated decay -1.70 -0.81
DRIMSeq SLC2A4RG ENST00000473157 processed transcript -2.30 -2.09
DRIMSeq CD46 ENST00000367041 protein coding -1.25 -0.59
DRIMSeq ST3GAL5 ENST00000393808 protein coding -0.96 -0.54
DRIMSeq ACO1 ENST00000379923 protein coding -1.38 -1.83
DRIMSeq PRODH ENST00000334029 protein coding -1.48 -1.39
DRIMSeq RPS9 ENST00000391752 protein coding 2.56 0.95
DRIMSeq LRTOMT ENST00000440313 protein coding 1.41 0.68
DRIMSeq LINC00499 ENST00000510736 lincRNA -1.14 -0.68
DRIMSeq RNF38 ENST00000377885 protein coding -0.98 -0.87
DRIMSeq APIP ENST00000527830 processed transcript -2.87 -2.49
DRIMSeq CNPY2 ENST00000548013 retained intron -0.79 -0.31
DRIMSeq LINC00499 ENST00000502757 lincRNA 0.93 0.54
DRIMSeq ACAA1 ENST00000452171 protein coding -1.26 -0.83
Each transcript is described by its Ensemble identifier (version 75). The effect size (ES) is relative to the controls, i.e. positive ES represents an increase in transcript
usage in PD relative to controls, negative ES a decrease. The p-value as reported by stageR for each tool separately (DEXSeq and DRIMSeq) is representative for the level
of significance after FWER control with α = 0.05 and is lower than 0.03 for all listed DTU events. The table is sorted by the p-value in increasing order and grouped by
the tool that identified the transcript
https://doi.org/10.1371/journal.pgen.1009182.t004
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Discussion
We report the first transcriptome-wide DTU study in PD. Our analyses reveal that multiple
DTU events occur in the PD brain and many of these are predicted to have a functional
impact. Interestingly, the vast majority of genes exhibiting DTU are not detected by conven-
tional DGE analysis on the same dataset. This is either because DTU occurs in low-expressed
isoforms, or due to antagonistic, inverse changes in other transcripts of the same gene, cancel-
ing out the net change at the gene expression level.
Our findings suggest that DTU events in PD may have important downstream conse-
quences for protein function, irrespective of whether there is a measurable difference in the
total gene expression levels. Changes in the relative expression of different transcripts of a gene
affect the ratio of the resulting protein isoforms and could, therefore, influence biological pro-
cesses through variation in function and/or subcellular localization. Moreover, switches may
occur between protein coding and non-coding transcript isoforms, thereby affecting the over-
all protein level. Changes in the usage ratios of low expressed and/or non-protein coding iso-
forms may also have important biological effects, as it has been shown that these are highly
cell- and tissue-specific, and have a substantial impact on the composition and function of the
proteome [5].
In our dataset, individuals with PD showed a significant decrease in the relative usage of a
THEM5 transcript variant that encodes the full-length THEM5 protein isoform, predicted to
localize to mitochondria. This isoform is involved in mitochondrial fatty acid metabolism by
exhibiting esterase activity with a preference for long and unsaturated fatty acid-CoA esters
[19]. Decreased THEM5 function has been shown to influence the remodeling process of mito-
chondrial inner membrane cardiolipin [19, 20], resulting in abnormal mitochondrial mor-
phology and impaired mitochondrial respiration [19], both of which occur in PD [18, 21]. A
concomitant increase in the relative expression of a shorter THEM5 isoform resulted in rela-
tively unchanged levels of total gene expression. However, as this isoform encodes a protein
lacking the first 37 N-terminal amino acids, it is unlikely to localize to mitochondria, and may
therefore not replace the full-length protein functionally [19].
A protein-coding transcript of the SLC16A1 gene was significantly down-regulated in the
PD brain and accompanied by an increase of similar magnitude in a non-protein coding tran-
script. SLC16A1 encodes a monocarboxylate transporter (MCT1) responsible for lactate and
pyruvate trafficking across cell membranes. MCT1 is the most abundant lactate transporter in
the central nervous system, where it is highly expressed in oligodendroglia. It has been shown
that MCT1 plays a key role in the energy homeostasis of neurons, by regulating lactate trans-
port between oligodendroglia and axons. MCT1 disruption causes axonal dysfunction and
neurodegeneration in cell and animal models and MCT1 levels have been found to be
decreased in patients and mouse models of ALS [22, 23].
Another gene of interest was BCHE, which showed a decreased usage of the protein-coding
full-length transcript, suggesting that the level of the functional full length protein isoform
may be decreased in PD. Interestingly, genetic variation in this gene has been associated with
Alzheimer’s disease [24], susceptibility to pesticide toxicity [25] and, more recently, with PD
[26].
In the few genes that were detected by both DTU and DGE analysis, DTU provided addi-
tional functional insight. Since changes in the relative isoform expression can occur in oppo-
site directions to the overall gene-level expression, transcript-level resolution is essential in
order to predict the functional consequences of altered expression.
Our analyses did not confirm a previous report of altered transcript expression in the
SNCA gene in the PD frontal cortex [12]. These findings were based on a small PD cohort
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(n = 5) with no reported neuropathological confirmation of the diagnosis. The fact that the
reported transcripts were confidently detected in our data but showed no evidence (or trend)
of altered relative expression in either of our cohorts, suggests that this effect, if real, is not a
general or common phenomenon in PD. Alternatively, the lack of replication may reflect dif-
ferent genetic backgrounds and environmental exposures in different populations (Spanish,
Norwegian and Dutch). The PRKN transcripts TV3 and TV12, which were reported to show
altered expression in PD in the same sample as SNCA [12, 13] did not show sufficient expres-
sion in our material to be confidently assessed for replication.
While most identified DTU genes in our results do not have a known role in PD, pathway
analyses showed significant enrichment in clusters associated with the pathophysiology of PD,
including reactive oxygen species (ROS) generation and protein degradation. These results
confirm that our findings are related to the biology of PD and highlight DTU analyses as a
complementary strategy to nominating novel disease candidate genes and processes.
A potential limitation in our study is posed by differences in cell-type composition between
brain tissue of patients and controls. We have recently shown that this can be an important
confounding factor in differential expression analysis of bulk brain tissue [18]. To mitigate this
problem, we accounted for differences in cellularity across samples by including cell type esti-
mates for specific cell types found to be significantly associated with disease status, as covari-
ates in our model. Notably, correcting for cell-type composition had only a minor effect in our
results, supporting the notion that most identified DTU events are not driven by differences in
cellularity between PD and controls.
While our top DTU findings replicate across the two independent cohorts, suggesting these
changes are robustly associated with PD, we nevertheless observe an overall low concordance
between the cohorts. This most likely reflects a combination of biological and technical factors,
including limited power due to the relatively small sizes of the cohorts, heterogeneous disease
biology and cell-composition, population-specific and/or brain bank-specific effects, differ-
ences in the age and RIN ranges. Differences between the cohorts were also evident in the fil-
tering results, whereby a larger number of transcripts in the replication cohort were filtered
out in comparison to the discovery cohort, as summarized in S5A Fig. We hypothesized that
this may be related to the overall higher RINs of the samples from the replication cohort. Tran-
scripts which were detected in the discovery cohort but not in the replication cohort showed a
negative correlation with RIN (S5B Fig), suggesting that lower RNA quality (reflected by lower
RIN values) is associated with higher transcript counts due to an increase in non-specific align-
ments in degraded samples.
Further replication in larger samples will be required in order to confirm and further dis-
sect the DTU landscape of the PD brain. Methodological limitations should also be considered.
While DRIMSeq was designed specifically for DTU analysis and assesses the relationship of
each transcript abundance relative to the total transcriptional output, it may have difficulties to
correctly estimate the dispersion for genes with a large number of isoforms [16]. This can
potentially lead to inaccurate transcript proportion estimations and increase the susceptibility
to false positive results, as suggested by the p-value distributions. Conversely, DEXSeq cannot
capture the transcript-gene relationship directly, which might explain its general lower sensi-
tivity compared to DRIMSeq.
Conclusion
In conclusion, our findings provide the first insight into the DTU landscape of PD. We show that
DTU is a prominent feature in the PD brain and may have important functional consequences by
altering the structural and functional composition of the proteome. We therefore propose that
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DTU analyses should be an essential component of transcriptomic studies, along with DGE anal-
yses, because they provide additional insight into the transcriptomic landscape and allow a more
accurate prediction of the functional consequences of detected changes in gene expression.
Methods
Cohorts
Fresh-frozen prefrontal cortex tissue (Brodmann area 9) was available from two independent
cohorts. The discovery cohort comprised individuals with idiopathic PD (n = 17) from the
Park West study, a prospective population-based cohort, which has been described in detail
[15], and demographically matched controls (n = 11). Samples were collected and stored in
our Brain Bank for Aging and Neurodegeneration. The replication cohort comprised individu-
als with idiopathic PD (n = 10) and demographically matched controls (n = 11) from the Neth-
erlands Brain Bank. The details of the cohorts are summarized in Table A in S1 File.
Ethics statement
Ethical permission for these studies was obtained from our regional ethics committee
“Regional Committee for Medical and Health Research Ethics”: REK 2017/2082, 2010/1700,
131.04 (REC, https://rekportalen.no/). Written formal informed consent was obtained from all
participants or their next of kin.
RNA sequencing
Total RNA was extracted from prefrontal cortex tissue homogenate for all samples using
RNeasy plus mini kit (Qiagen) with on-column DNase treatment according to manufacturer’s
protocol. Final elution was made in 65 μl of dH2O. The concentration and integrity of the
total RNA was estimated by Ribogreen assay (Thermo Fisher Scientific), and Fragment Ana-
lyzer (Advanced Analytical), respectively. Five hundred ng of total RNA was required for pro-
ceeding to downstream RNA-seq applications. First, ribosomal RNA (rRNA) was removed
using Ribo-Zero™ Gold (Epidemiology) kit (Illumina, San Diego, CA) using manufacturer’s
recommended protocol. Immediately after the rRNA removal the RNA was fragmented and
primed for the first strand synthesis using the NEBNext First Strand synthesis module (New
England BioLabs Inc., Ipswich, MA). Directional second strand synthesis was performed using
NEBNext Ultra Directional second strand synthesis kit. Following this the samples were taken
into standard library preparation protocol using NEBNext DNA Library Prep Master Mix Set
for Illumina with slight modifications. Briefly, end-repair was done followed by poly(A) addi-
tion and custom adapter ligation. Post-ligated materials were individually barcoded with
unique in-house Genomic Services Lab (GSL) primers and amplified through 12 cycles of
PCR. Library quantity was assessed by Picogreen Assay (Thermo Fisher Scientific), and the
library quality was estimated by utilizing a DNA High Sense chip on a Caliper Gx (Perkin
Elmer). Accurate quantification of the final libraries for sequencing applications was deter-
mined using the qPCR-based KAPA Biosystems Library Quantification kit (Kapa Biosystems,
Inc.). Each library was diluted to a final concentration of 12.5 nM and pooled equimolar prior
to clustering. 125 bp Paired-End (PE) sequencing was performed on an Illumina HiSeq2500
sequencer (Illumina, Inc.) at a target depth of 60 million reads per sample.
FASTQ files were trimmed using Trimmomatic [27] to remove potential Illumina adapters
and low quality bases with the following parameters:
ILLUMINACLIP:truseq.fa:2:30:10
LEADING:3 TRAILING:3 SLIDINGWINDOW:4:15.
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FASTQ files were assessed using fastQC [28] prior and following trimming.
Transcript quantification
We used Salmon [29] with the fragment-level GC bias correction option (--gcBias) and
the appropriate option for the library type (-l ISR) to quantify transcript expression in
pseudo-alignment mode, using the GRCh37 genome as a reference. X and Y chromosomes
were excluded from the GRCh37 reference genome, restricting quantification to transcripts
located on autosomes.
Transcripts per million (TPM) values obtained with Salmon were scaled using the R pack-
age tximport [30] with the scaling method scaledTPM, the favored scaling method for DTU
[31].
DTU analyses and quality control
DTU analyses estimate transcript usage and detect changes in the relative contribution of a
transcript to the overall expression of the gene. Transcript usage corresponds to the transcript-







where nj equals the number of transcripts of gene j and ti is the expression count of transcript
i. Hence, differential transcript usage describes a change in proportions between the groups
(PD and controls).
For our analysis, we employed an alignment-free abundance estimation method [29],
which enabled read quantification at the transcript level directly, as opposed to traditional read
alignment methods that require bin or exon read counting and subsequent summarization to
transcript level.
We performed DTU analysis between PD and controls using two alternative approaches
implemented in the tools DRIMSeq [16] and DEXSeq [17]. While DEXSeq was designed for
detecting differential exon usage, it is also suitable for assessing DTU by using estimated tran-
script abundances directly [6, 31, 32]. DRIMSeq was developed specifically for DTU analyses
and is based on estimated transcript counts [16]. These methods assess alternative splicing by
directly identifying transcripts that are differentially used, rather than detecting specific splice
events. Both methods have shown comparable performance in benchmarks with simulated
data [16, 31, 32]. A further advantage was that these tools allow for the inclusion of known
covariates into the model design. DRIMSeq assumes a Dirichlet multinomial model for each
gene and estimates a gene-wise precision parameter, whereas DEXSeq assumes a negative
binomial distribution for counts of each transcript and estimates a transcript-wise dispersion
parameter [31]. It is worth noting that DRIMSeq bases its analyses directly on the calculated
transcript proportions, thereby modeling the correlation among transcripts in their parent-
gene directly, whereas those correlations may not be accurately captured by DEXSeq, as it
models each transcript separately and accounts for gene-transcript interaction with a covariate
in its model design [31].
Due to the complexity of the human transcriptome in terms of diversity and number of tran-
scripts per gene, DTU methodologies tend to exhibit a worse performance considering the false
discovery rate (FDR) when compared to simpler organisms [6]. However, FDR can be reduced
considerably if the collection of transcripts undergoes filtering prior to analysis [6]. Transcript
filtering, in addition, alleviates the DRIMSeq-specific difficulty of capturing the full bandwidth
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of transcript dispersion through the common gene-level dispersion estimate [16], which results
otherwise in a decrease in performance for genes with increasing number of transcripts. We
thus excluded lowly expressed transcripts with a soft filter, allowing for a certain percentage of
all samples to have a transcript expression below the given threshold. This filtering methodol-
ogy was chosen over hard filtering in order to avoid overlooking cases of DTU driven by lack of
expression in one of the groups being compared, which would have been the case with a hard
threshold filtering. Using the filtering method available in the DRIMSeq package, we excluded
transcripts for which more than n = min(#Controls, #PD) samples did not reach 10
read counts or for which their relative contribution to the overall gene expression was smaller
than one percent. In addition, we filtered out genes with less than 10 counts in any one sample.
To investigate changes in transcript usage between PD and controls, the resulting filtered set of
transcript-level counts were used as an input for both DEXSeq and DRIMSeq as recently sug-
gested by [31]. Analyses were carried out independently on both cohorts.
Model design
Sources of variation in our data were identified using principal component analysis (PCA) at
the gene-level. RNA integrity number (RIN) correlated highly with the first principal compo-
nent, indicating that RNA quality represents a major source of variation in the expression data.
Relative cellular composition in our samples was obtained from our previous study [18]
using marker gene profiles (MGPs) [33, 34]. In summary, an MGP was calculated for each of
the main cortical cell types (neurons, oligodendrocytes, astrocytes, endothelial, and microglia)
by performing a PCA on the log-transformed expression (in counts per million) of cell type-
specific marker genes from the NeuroExpresso database [33] and extracting the first principal
component. MGPs for oligodendrocyte and microglia showed a significant association with
the disease status (controls vs PD) and were accounted for in the DTU models together with
RIN, gender, and age.
To explore the effect of accounting for disease-associated MGPs in the DTU results, we
compared the two alternative designs, with and without oligodendrocyte and microglia MGPs.
Accounting for cellular composition slightly increased the discovery signal, identifying a few
more DTU genes with both DRIMSeq and DEXSeq. This effect was minor, however, as most
DTU genes and events were identified irrespective of whether cell-type composition was
accounted for or not (S3 and S4 Figs).
Statistical testing
The results of the DTU analyses were further processed with StageR [35]. Gene-level aggre-
gated p-values (q-values) as well as transcript-level p-values were passed to stageR for a two-
stage screening of significance. For DEXSeq, nominal p-values of all transcripts of a gene were
aggregated to a q-value and corrected using the function perGeneQvalue. For DRIMSeq, nomi-
nal p-values were already reported at the gene-level and further corrected within stageR using
the Benjamini-Hochberg (BH) FDR procedure. To control the FWER, transcript-level signifi-
cance was corrected within-gene, if the gene passed the first screening stage of stageR, with
respect to the FDR controlled gene-level significance (q-value). Transcripts of genes which did
not pass the first screening stage, were not further assessed for significance at the transcript-
level. Nominal transcript-level p-values of both tools were adjusted within StageR using an
adapted Holm-Shaffer family-wise error rate (FWER) correction method specifically designed
for DTU analysis [35].
We define a transcript as a DTU event, if the FWER-controlled p< α with α = 0.05. Simi-
larly, we define as DTU gene any gene that exhibits at least one DTU event.
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Similarly, we define α = 0.05 for nominal significance.
DTU pathway enrichment analysis
To assess the enrichment of DTU genes in predefined functional gene sets (pathways), we
employed the enrichment function of the stringDB R package [36]. DTU genes identified in
our discovery cohort were used as hits and all genes surviving the filtering step during pre-pro-
cessing were used as background. Enrichment was tested for pathways defined by the Genome
Ontology (GO) [37, 38]. Each of the three GO categories (Biological Process, Molecular Func-
tion, Cellular Compartment) was tested separately. To reduce redundancy of the top most
enriched pathways (FDR< 0.05), we performed a clustering in each of the three GO catego-
ries. Pathways were clustered by iteratively joining nearest neighbors based on pathway simi-
larity, which we defined with the Cohen’s kappa coefficient (κ). The similarity of newly
formed clusters and unvisited neighbours was iteratively recalculated, until no two clusters’ κ
was higher than a chosen threshold of 0.4. Each cluster was given a representative title, chosen
from the names of all the pathways in a cluster. The choice of the cluster title depended on the
pathway size, pathway significance or chosen randomly if none of the previous criteria were
sufficient. Finally, each pathway cluster was assigned a p-value by aggregating p-values of all
cluster members with the Fisher method.
For specific cases of isoform switches between protein coding transcripts, we used the
tool DeepLoc [39] to predict subcellular localization by retrieving the encoded amino acid
sequence from the Ensembl release 75.
RNA extraction, cDNA synthesis and quantitative PCR analysis
RNA extraction was carried out using the RNeasy Lipid Tissue Mini Kit (QIAGEN 74804),
starting with ca. 20 mg brain tissue from three individuals with PD and three controls. 500 ng
total RNA were subjected to cDNA synthesis using the SuperScript IV VILO Master Mix with
ezDNase Enzyme (Thermofisher Scientific 11766500). Experiments were carried out in tripli-
cates starting with a new cDNA synthesis from aliquoted total RNA. For the SYBR Green
quantitative PCR analysis, the PowerUp SYBR Green Master Mix (Thermofisher Scientific,
A25776) was used with a thermal cycling of one cycle at 95˚C for 20s and 40 cycles at 95˚C for
3s and 60˚C for 30s on a StepOnePlus instrument (Thermofisher Scientific), and with the
primers listed in Table 5.
Table 5. qPCR primer sequences.
Transcript ID Primer name Primer sequence
ENST00000374861 ZNF189_374861 fw 5‘-TGGGGTTCGGGGTTGGGG-3‘
ENST00000374861 ZNF189_374861 rv 5‘-CGGTCACGACCCCAACAGC-3‘
ENST00000339664 ZNF189_339664 fw 5‘-GATGGCTTCCCCGAGCCC-3‘
ENST00000339664 ZNF189_339664 rv 5‘-ACACAGCCACATCCTCAAATG-3‘
ENST00000259395 ZNF189_259395 fw 5‘-GAGATGGCTTCCCCGAGCC-3‘
ENST00000259395 ZNF189_259395 rv 5‘-CTTATTTTCTCAGGCCGATTTATC-3‘
ENST00000540653 BCHE_540653 fw 5‘- GCAAACTTTGCCATCTTTGTTG-3‘
ENST00000540653 BCHE_540653 rv 5‘- CTTGTGCTATTGTTCTGAGTC-3‘
ENST00000264381 BCHE_264381 fw 5‘- AGATCCATAGTGAAACGGTGG-3‘
ENST00000264381 BCHE_264381 rv 5‘- CTTGTGCTATTGTTCTGAGTC-3‘
GAPDH Assay ID Hs00266705_g1 (Thermofisher)
https://doi.org/10.1371/journal.pgen.1009182.t005
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Supporting information
S1 Fig. Diagnostic plots. Data points in all plots represent one transcript, with coloring show-
ing significant transcripts (α = 0.05) in red. P-values (uncorrected) are displayed as (−log10(p-
value)). A: Volcano plot displaying the effect size (as estimated by the respective tool) in the x-
axis and the p-value on the y-axis. Triangles mark extreme p-value outliers that were adjusted
to fit into the plot. B: MA plot visualizing a transcript’s significance as a function of its mean
expression over all samples. C: Density ridges display the distribution of gene-level significance
(−log10(p-value)) per gene type, where genes are grouped according to the number of tran-
scripts they have after filtering. The color gradient was applied to visualize the p-value scale.
The vertical dashed line corresponds to a p-value of 0.05.
(TIFF)
S2 Fig. Concordance between DEXSeq and DRIMSeq in the replication cohort. Estimated
transcript usage effect sizes are shown for each transcript of the replication cohort, with results
from each tool on each of the axes (DRIMSeq x-axis, DEXSeq y-axis). Points situated on the
diagonal represent transcripts with equal effect size estimations of both tools; points situated
inside the first and third quadrant of the coordinate system represent transcripts agreeing in
direction according to both tools (i.e. up-regulated in PD: first quadrant, down-regulated in
PD: third quadrant). A: Transcripts that did not reach statistical significance in the DTU analy-
ses by either DRIMSeq or DEXSeq. B Transcripts found to be significant by both tools. C:
Transcripts found to be significant by DEXSeq only. D: Transcripts found to be significant by
DRIMSeq only. Transcripts identified as DTU events (significant after p-value adjustment) are
coloured according to the plot legend. Red: transcript identified as a DTU event by both tools,
yellow: transcript identified as a DTU event by DRIMSeq only, grey: transcript either didn’t
survive FWER correction by neither tool or wasn’t nominally significant beforehand. (Tran-
scripts can appear significant after FWER control even if they weren’t nominally significant,
due to StageR assigning significance by relying on the assumption that if DTU is occurring in
the gene (that is: the gene has passed the screening stage) and one of its transcripts is signifi-
cant, the other must subsequently also take part in the DTU to compensate).
(TIFF)
S3 Fig. Overlap DTU genes and events, with and without cell correction. DTU genes (A, B)
and events (C, D) resulting from the analysis which included cell type estimations (purple) are
overlapped with the results of the analysis where differences in cell types were not taken into
account (turquoise). Only DTU events which were identified in the discovery cohort and
replicated in the independent replication cohort were considered for this plot. A: DTU genes
identified by DRIMSeq. B: DTU genes identified by DEXSeq. C: DTU events identified by
DRIMSeq. D: DTU events identified by DEXSeq.
(TIFF)
S4 Fig. Characteristics of the replicated DTU genes and events depicted as heatmaps. Repli-
cated DTU events (significant after OFWER correction in the discovery cohort, agreeing on
the direction of change across cohorts and nominally significant at alpha = 0.05 in the replica-
tion cohort) are arranged in the y-axis. A: transcript’s adjusted p-value (white cells indicate
adjusted p-value >= 0.05). B: Transcript’s log fold change (white cells correspond to tran-
scripts not identified as DTU events). C: Transcript’s nominal (uncorrected) p-value. In all
heatmaps, characteristics are grouped by model design (i.e. with (“Incl. MGPs”) or without
(“w/o MGPs”) accounting for MGPs) and by tool (DRIMseq or DEXSeq).
(TIFF)
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S5 Fig. Effect of pre-filtering on the number of transcripts per cohort. A: Venn diagram for
the sets of transcripts which survived pre-filtering in each cohort. Number of transcripts that
survived filtering in the replication cohort (green), in the discovery cohort (red), and number
of transcripts identified as DTU events in the discovery cohort (blue). B: Distribution of the
correlation coefficients between transcript abundance (TPM) and sample RIN for non-concor-
dant transcripts (i.e. transcripts removed during the pre-filtering in the replication cohort, but
not in the discovery cohort) and concordant transcripts (i.e. transcripts that survived pre-fil-
tering in both cohorts).
(TIFF)
S1 File. A: Cohort demographic and experimental information. B: DTU events. Table of iden-
tified DTU events, grouped by cohort (replication, discovery) and tool (DRIMSeq, DEXSeq).
Gene-level and transcript-level p-values as reported by stageR (after FWER correction). Effect
size corresponds to the coefficient of the condition variable (Control, PD) in the analysis
model.
(XLSX)
S1 Table. Overrepresentation analysis of DTU events in transcript biotypes. P-values and
odds ratios were determined by Fisher’s exact test. The contingency table was built up separating
transcripts by whether or not they were identified as DTU events and whether they were defined
as the biotype of interest (as defined by Ensembl version 75). The rows are grouped by the tool
which identified the DTU event and sorted by increasing p-value of the Fisher’s exact test.
(PDF)
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21. Burté F, Houghton D, Lowes H, Pyle A, Nesbitt S, Yarnall A, et al. Metabolic profiling of Parkinson’s
disease and mild cognitive impairment. Movement Disorders. 2017; 32(6):927–932. PMID:
28394042
22. Kaji S, Maki T, Kinoshita H, Uemura N, Ayaki T, Kawamoto Y, et al. Pathological endogenous α-synu-
clein accumulation in oligodendrocyte precursor cells potentially induces inclusions in multiple system
PLOS GENETICS Differential transcript usage in the Parkinson’s disease brain
PLOS Genetics | https://doi.org/10.1371/journal.pgen.1009182 November 2, 2020 23 / 24
atrophy. Stem cell reports. 2018; 10(2):356–365. https://doi.org/10.1016/j.stemcr.2017.12.001 PMID:
29337114
23. Lee Y, Morrison BM, Li Y, Lengacher S, Farah MH, Hoffman PN, et al. Oligodendroglia metabolically
support axons and contribute to neurodegeneration. Nature. 2012; 487(7408):443. https://doi.org/10.
1038/nature11314 PMID: 22801498
24. Ramanan VK, Risacher SL, Nho K, Kim S, Swaminathan S, Shen L, et al. APOE and BCHE as modula-
tors of cerebral amyloid deposition: a florbetapir PET genome-wide association study. Molecular psychi-
atry. 2014; 19(3):351–357. https://doi.org/10.1038/mp.2013.19 PMID: 23419831
25. Lockridge O, Masson P. Pesticides and susceptible populations: people with butyrylcholinesterase
genetic variants may be at risk. Neurotoxicology. 2000; 21(1-2):113–126. PMID: 10794391
26. Rösler TW, Salama M, Shalash AS, Khedr EM, El-Tantawy A, Fawi G, et al. K-variant BCHE and pesti-
cide exposure: Gene-environment interactions in a case–control study of Parkinson’s disease in Egypt.
Scientific reports. 2018; 8(1):16525. https://doi.org/10.1038/s41598-018-35003-4
27. Bolger AM, Lohse M, Usadel B. Trimmomatic: a flexible trimmer for Illumina sequence data. Bioinfor-
matics. 2014; 30(15):2114–2120. https://doi.org/10.1093/bioinformatics/btu170 PMID: 24695404
28. Andrews S, Krueger F, Segonds-Pichon A, Biggins L, Krueger C, Wingett S. FastQC; 2012. Babraham
Institute.
29. Patro R, Duggal G, Kingsford C. Salmon: accurate, versatile and ultrafast quantification from RNA-seq
data using lightweight-alignment. BioRxiv. 2015; p. 021592.
30. Soneson C, Love MI, Robinson MD. Differential analyses for RNA-seq: transcript-level estimates
improve gene-level inferences. F1000Research. 2015; 4. https://doi.org/10.12688/f1000research.7563.
1 PMID: 26925227
31. Love MI, Soneson C, Patro R. Swimming downstream: statistical analysis of differential transcript
usage following Salmon quantification. F1000Research. 2018; 7. https://doi.org/10.12688/
f1000research.15398.1 PMID: 30356428
32. Anders S, Reyes A, Huber W. Detecting differential usage of exons from RNA-seq data. Genome
research. 2012; 22(10):2008–2017. https://doi.org/10.1101/gr.133744.111 PMID: 22722343
33. Mancarci BO, Toker L, Tripathy SJ, Li B, Rocco B, Sibille E, et al. Cross-laboratory analysis of brain cell
type transcriptomes with applications to interpretation of bulk tissue data. Eneuro. 2017; 4(6). https://
doi.org/10.1523/ENEURO.0212-17.2017 PMID: 29204516
34. Toker L, Mancarci BO, Tripathy S, Pavlidis P. Transcriptomic evidence for alterations in astrocytes and
parvalbumin interneurons in subjects with bipolar disorder and schizophrenia. Biological psychiatry.
2018; 84(11):787–796. https://doi.org/10.1016/j.biopsych.2018.07.010 PMID: 30177255
35. Van den Berge K, Soneson C, Robinson MD, Clement L. stageR: a general stage-wise method for con-
trolling the gene-level false discovery rate in differential expression and differential transcript usage.
Genome biology. 2017; 18(1):151. https://doi.org/10.1186/s13059-017-1277-0 PMID: 28784146
36. Szklarczyk D, Gable AL, Lyon D, Junge A, Wyder S, Huerta-Cepas J, et al. STRING v11: protein–pro-
tein association networks with increased coverage, supporting functional discovery in genome-wide
experimental datasets. Nucleic acids research. 2019; 47(D1):D607–D613. https://doi.org/10.1093/nar/
gky1131 PMID: 30476243
37. Ashburner M, Ball CA, Blake JA, Botstein D, Butler H, Cherry JM, et al. Gene ontology: tool for the unifi-
cation of biology. Nature genetics. 2000; 25(1):25–29. https://doi.org/10.1038/75556 PMID: 10802651
38. Consortium GO. The gene ontology resource: 20 years and still GOing strong. Nucleic acids research.
2019; 47(D1):D330–D338. https://doi.org/10.1093/nar/gky1055
39. Almagro Armenteros JJ, Sønderby CK, Sønderby SK, Nielsen H, Winther O. DeepLoc: prediction of
protein subcellular localization using deep learning. Bioinformatics. 2017; 33(21):3387–3395. https://
doi.org/10.1093/bioinformatics/btx431 PMID: 29036616
PLOS GENETICS Differential transcript usage in the Parkinson’s disease brain
PLOS Genetics | https://doi.org/10.1371/journal.pgen.1009182 November 2, 2020 24 / 24
